See the original post:
PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024
Better Choice Research Partner, Aimia Pet HealthCo Inc., Signs Second R&D Partnership Agreement with KGK Science for Development of GLP1 Supplement…
Kane Biotech Announces Special Meeting of Shareholders
Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
Go here to see the original:
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children…
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
Change of management at NTG Nordic Transport Group A/S
See the article here:
Change of management at NTG Nordic Transport Group A/S
SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
See the article here:
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04